HISTORY & PRINCIPLES
RegenMed is a U.S. company, operating globally in the healthcare data space. It helps all healthcare stakeholders generate strategic and sustained value from real-world evidence. RWE is essential to value-based care, health equity and other fundamental elements of 21st century healthcare.
RegenMed is founded to support the evidence-based clinical translation of regenerative medicine -- a market valued at $20 billion, with a forecast 16% annual growth rate.
RegenMed introduces “Circles” – a turnkey integration of the technology and processes needed to generate clinical, scientific, and financial value from real-world evidence.
Physicians and industry launch Circles in orthopedics, neurology, endocrinology, and other disciplines. Launch of Circle Academies. Issuance of United States patent for inCytes™/Benchmarc™.
2024 AND BEYOND
Healthcare in this century will depend on value-based medicine, improved clinician and patient experiences, and greater health equity. Through Circles, RegenMed will continue to establish value-added partnerships with providers, industry, and societies around the world.
Real-world evidence is essential to value-based care, health equity, and more efficient clinical translation of medical advances.
RWE is based on validated, longitudinal and contextually correlated data arising from everyday clinical interventions.
The most valuable RWE results from ethical, data-driven collaboration among practitioners, medical scientists and industry.
In generating RWE, the user experience for clinicians and patients is as important as the technical platform.
Properly designed and executed, RWE programs can materially reduce healthcare costs.
Integrated RWE programs generate sustainable net return on investment and strategic value for all healthcare constituencies.